Hepcidin蛋白与前列腺癌骨转移的相关性研究

Role of Hepcidin in prostate cancer patients with bone metastasis

目的观察前列腺癌骨转移患者血清中IL-6、sTIR、BMP6等指标的变化，分析3个指标之间的相关性，探讨Hepcidin蛋白在前列腺癌骨转移中的作用。方法选取2012年1月至2012年3月前列腺癌骨转移患者25例、前列腺癌无骨转移患者30例和BPH患者30例，年龄55—75岁，平均67岁。前列腺癌骨转移组PSA20．0～1500．0μg／L，中位数138．0μg／L；无骨转移组PSA3．5～28．2μg／L，中位数10．2μg／L；BPH组PSA0．3—14．2μg／L，中位数3．7μg／L。采用竞争性同相酶联免疫分析法（ELISA）分别测定血清Hepcidin、IL-6、sTIR、BMP6的表达。结果前列腺癌骨转移组、无骨转移组、BPH组血清Hepcidin含量分别为（67．7±40．6）、（37．5±15．3）、（34．3±10．7）斗g／L，IL-6含量分别为（22．5±22．1）、（12．6±10．2）、（10．2±8．4）IXg／L，sTIR含量分别为（5．7±2．6）、（7．9±3．6）、（8．2±5．7）μg／L，BMP6含量分别为（429．3±188．4）、（325．7±40．3）、（296．5±38．7）μg／L，血常规Hb（131．1±13．6）、（137．8±12．3）、（141．9±11．4）g／L。前列腺癌骨转移组各项检查指标与无骨转移组和BPH组比较差异均有统计学意义（P〈0．05）。骨转移组Hepeidin与IL-6、sTIR、BMP6表达有相关性，相关系数分别为0．972、-0．987、0．971，差异均有统计学意义（P〈0．05）；与Hb无相关性，相关系数为0．201，差异无统计学意义（P〉0．05）。结论前列腺癌骨转移患者的血清Hepeidin表达增高，可以作为晚期前列腺癌骨转移诊断以及预后判断的敏感指标。

Objective To detect the expression and correlation of serum Hepcidin, IL-6, sTfR, BMP6 diversity and explore the role of serum Hepcidin in prostate cancer with bone metastasis. Methods From January 2012 to March 2012, serum Hepcidin, IL-6, sTfR, BMP6 diversity were tested by ELISA in 25 prostate cancer patients with bone metastasis, 30 prostate cancer patients without bone metastasis and 30 patients with BPH were used as the control group. The mean patient＇s age was 67 years （ range from 55 to 75 years）. In prostate cancers with bone metastasis group, the mean PSA base line was 138.0μg/L （ranged from 20.0 - 1500 p.g/L） , the prostate cancers without bone metastasis group, mean PSA was 10.2 μg/L （ranged from 3.5 -28.2 μg/L）, and in BPH group, the mean PSA was 3.7μg/L （ranged from 0.3 - 14.2 μg/L）. Venous blood samples were taken in fasting mornings, then stored 3 ml in EDTA anticoagulant vacuum tube and centrifuged at 4℃ for 10 min, the isolated serum were then preserved in -80 ℃ refrigerator. The competitive in-phase enzyme-linked immunoassay （ELISA） was used to detect serum Hepeidin, IL-6 and sTfR and BMP6 levels. Results Serum Hepcidin expressions in three groups were 67.7 ± 40.6 μg/L, 37.5 ± 15.3 μg/L and 34.3 ± 10.7 μg/L, respectively. For prostate cancers with bone metastasis group, serum Hepcidin expression were higher than control group （ P 〈 0.05 ）, and associated with IL-6 （22.5 ±22.1 μg/L）, sTfR （5.7 ± 2.6 μg/L）, BMP6 （429.3 ± 188.4 μg/L）, correlation coefficients were 0. 972, -0. 987, 0. 971 （P 〈 0.05 ）. Conclusions Increased serum Hepeidin level might be a sensitive index for diagnosis and prognosis of prostate cancers with bone metastasis.